Emgality®: a migraine treatment that can fit into your patient’s life1
Learn more
Want to learn about Emgality? Register here to receive updates from Lilly.
References:
- Data on File. Lilly, USA, LLC. DOF-GZ-US-0181.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0190.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0189.
- Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0085.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0060.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0071.
- Camporeale A, Kudrow D, Sides R, et al. A phase 3, long-term, open-label safety study of galcanezumab in patients with migraine. BMC Neurol. 2018;18(1):188. doi:10.1186/s12883-018-1193-2.
- Stauffer VL, Dodick DW, Zhang Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol. 2018;75(9):1080-1088.
- Skljarevski V, Matharu M, Millen BA, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the EVOLVE-2 Phase 3 randomized controlled clinical trial. Cephalalgia. 2018;38(8):1442-1454.
- Detke HC, Goadsby PJ, Wang S, et al. Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology. 2018;91(24):e2211-e2221.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0107.
- Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:90.doi:10.1186/s12883-020-1609-7.
- Data on File. Lilly USA, LLC. DOF-GZ-US-0013.
- Ailani J, Burch RC, Robbins MS; the Board of Directors of the American Headache Society. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;00:1-19.